<HOME PAGE <PREVIOUS PAGE

  1. Denning DW, Ward PN, Fenelon LE, Benbow EW. Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis. Infect Immun 1992; 60: 5153-5156.
  2. Moore CB, Law D, Denning DW. In vitro activity of D0870 compared with amphotericin B and itraconazole against Aspergillus spp. J Antimicrob Chemother 1993; 32: 831-836.
  3. Law D, Moore CB, Denning DW. A new bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrobial Agents Chemother 1994; 38: 1561-1566.
  4. Baily GG, Perry FM, Denning DW, Mandal BK. Management of candidiasis after failure of fluconazole in an HIV cohort. AIDS 1994; 8: 787-792.
  5. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MGL, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994; 34: 659-668.
  6. Hall LA, Denning DW. Oxygen requirements of Aspergillus species. J Med Microbiol 1994; 41: 311-315.
  7. Ng TTC, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994; 140: 2475-2480.
  8. Birch M, Nolard N, Shankland G, Denning DW. DNA typing of epidemiologically-related isolates of Aspergillus fumigatus. Infect Epidemiol 1995; 114: 161-168.
  9. Wardle H, Moore C, Law D, Mason C, Denning DW. In vitro activity of D0870 compared with those of other azoles against fluconazole resistant Candida spp. Antimicrob Agent Chemother 1995; 39: 868-871.
  10. Denning DW, Hall L, Jackson M, Hollis S. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Antimicrob Agents Chemother 1995; 39: 1809-1814.
  11. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL. Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett 1995; 131: 337-341.
  12. Essayag SM, Burnie JP, Baily GG, Denning DW. Karyotyping of fluconazole-resistant yeasts reported on phenotype as Candida krusei or Candida inconspicua. Intern J Syst Bacteriol 1996:46:35-40.
  13. Birch M, Robson G, Law D, Denning DW. Evidence of multiple phospholipase activities of Aspergillus fumigatus. Infect Immun 1996;64:751-755.
  14. Law D, Birch M, Denning DW. Rapid genotyping of Escherichia coli 0157 isolates by random amplification of polymorphic DNA. Eur J Clin Microbiol Infect Dis 1996; 15: 297-302.
  15. Law D, Moore CB, Joseph LA, Keaney MGL, Denning DW. High incidence of antifungal drug resistance in Candida tropicalis. Int J Antimicrob Ag 1996;7:241-245.
  16. Wardle H, Law D, Denning DW. In vitro activity of pradimicin against fluconazole resistant Candida spp. Antimicrobial Ag Chemoth 1996; 40: 2229-2231.
  17. Venkateswarlu K, Denning DW, Manning NJ, Kelly SL. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Ag Chemother 1996; 40: 2443-2446.
  18. Hood SV, Moore CB, Denning DW. The isolation of Candida norvegensis from clinical specimens: 4 case reports. Clin Infect Dis, 1996; 23: 1185-1187.
  19. Venkateswarlu K, Denning DW, Kelly SL. Inhibition and interaction of sterol 14?-demethylase of Candida krusei with azole antifungal drugs. J Med Vet Mycol 1997;35:19-25.
  20. Nho S, Anderson MJ, Moore CB, Denning DW. Species differentiation by internal transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua and Candida norvegensis strains. J Clin Microbiol 1997;35:1036-1039.
  21. Denning DW, Venkateswarlu K, Oakley K, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Ag Chemother 1997; 41: 1364-1368.
  22. Venkateswarlu K, Denning DW, Kelly SL. In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei. J Antimicrob Chemother 1997; 39: 731-736.
  23. Law D, Moore CB, Denning DW. Amphotericin B resistance testing of Candida spp: a comparison of methods. J Antimicrob Chemother 1997; 40: 109-112.
  24. Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with amphotericin B and itraconazole against Aspergillus spp. Antimicrob Ag Chemother 1997;41:1124-1126.
  25. Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Ag Chemother 1997;41:1504-1507.
  26. Baily GG, Moore CB, Essayag SM, de Wit S, Burnie JP, Denning DW. Candida inconspicua, a fluconazole resistant Candida species in HIV patients. Clin Infect Dis 1997;25:161-163.
  27. Birch M, Drucker DB, Boote V, Denning DW. Prevalence of phthoic acid in Aspergillus spp. J Met Vet Mycol 1997;35:143-145.
  28. Takasuka T, Baily GG, Birch M, Anderson M, Law D, Denning DW. Variation in morphotype, karyotype and DNA type in fluconazole resistant C.albicans from an AIDS patient. J Infection 1998;36:57-62.
  29. Law D, Moore CB, Denning DW. The activity of SCH 56592 compared with fluconazole and itraconazole against 100 azole resistant yeasts. Antimicrob Ag Chemother 1997;41:2310-2311.
  30. Denning DW, Radford SA, Oakley K, Hall L, Johnson EM, Warnock DW. Correlation between in- vitro susceptibility testing to itraconazole and in-vivo outcome for Aspergillus fumigatus infection. J Antimicrob Chemother 1997;40:401-414.
  31. Grady R, Anderson M, Drucker D, Denning DW. Partial 16S rDNA analysis of oral Treponema J Med Microbiol 1997; 8 (Suppl 1) S24.
  32. Denning DW, Baily GG, Hood SV. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis 1997;16: 261-280.
  33. Carlson GL, Birch M, Mughal MM, Denning DW. Aspergillus wound infection following laparostomy. J Infect 1996; 33: 119-122.
  34. Hood SV, Moore CB, Cheesbrough JS, Mene A, Denning DW. Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine. Br J Dermatol 1997;136:953-956.
  35. Hood SV, Moore CB, Denning DW. Neurospora sitophila pulmonary infection in a patient with AIDS. AIDS Patient Care and STDs. 1997; 11:219-222.
  36. Hood SV, Bonnington A, Evans J, Denning DW. Impact of HIV protease inhibitors on the incidence of oropharyngeal candidiasis in AIDS. AIDS 1998, in press.
2001
  1. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001;7:11-6.
  2. Mosquera J, Warn PA, Morrisey J, Moore CB, Gil-Lamaignere C, Denning DW. Susceptibility testing of A. flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Ag Chemother 2001:45;1456-62.
  3. Wenisch C, Moore CB, Krause R, Presterl E, Pichna P, Denning DW. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. J Clin Microbiol 2001;39:2458-62.
  4. Heald A, O'Halloran DJ, Richards K, Webb F, Jenkins S, Denning DW, Young RJ. Fungal infection of the diabetic foot : Two distinct syndromes. Diabetic Med 2001;18:567-72.
  5. Denning DW, Griffiths CEM. Photosensitivity related to the novel triazole antifungal agent voriconazole. J Exp Dermatol 2001;26:648-53.
  6. Moore CB, Walls CM, Denning DW. In vitro activity of terbinafine against Aspergillus species and comparison with itraconazole and amphotericin B. Antimicrob Ag Chemother 2001;45:1882-5.
  7. Mosquera J, Warn PA, Rodriguez-Tudela JL, Denning DW. Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. J Antimicrob Chemother 2001;48:583-6.
2002
  1. Sivakumaran S, Bridge P, Roberts P. Genetic relatedness among Filobasidiella species. Mycopathologia 2002;156:157-62.
  2. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Donnelly PJ, Ruhnke M, Lode H. The efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
  3. Mosquero J, Denning DW. Azole cross resistance in Aspergillus fumigatus. Antimicrob Ag Chemother 2002;46:556-557.
  4. Denning DW, Anderson MJ, Turner G, Latgé JP, Bennett JW. Sequencing of the Aspergillus fumigatus genome. Lancet Infect Dis 2002;2:251-3.
  5. Slaven JW, Anderson MJ, Sanglard D, Dixon GJ, Bille J, Roberts IS, Denning DW. Induced expression of a novel Aspergillus fumigatus ABC transporter gene, atrf in response to itraconazole. Fung Genet Biol 2002;36:199-206..
  6. Mosquero J, Sharp A, Moore CB, Warn PA, Denning DW. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002;50:189-94.
  7. Warn PA, Sharp A, Morrissey G, Denning DW. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2002;50:1071-4.

2003

  1. Moore CB, Walls CM, Denning DW. Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine. J Antimicrob Chemother. 2003;51:297-304. 
  2.  Warn PA, Morrissey G, Morrissey J, Denning DW. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003;51:913-9. 
  3. Warn PA, Brampton MW, Sharp A, Morrissey G, Steel N, Denning DW, Priest T. Development of  non-invasive body temperature measurement in mice. Lab Anim 2003;37:126-31.
  4. Cuenca-Estrella M, Moore CB, Barchiesi F, Bille J, Chryssanthou E, Denning DW, Donnelly JP, Dromer F, Dupont B, Rex JH, Richardson MD, Sancak B, Verweij PE, Rodríguez-Tudela JL Multicentre Evaluation of the Reproducibility of the Proposed Antifungal Susceptibility Testing Method of the Antifungal Susceptibility Testing Subcommittee of The European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2003;9:467-74.  
  5. Denning DW, Riniotis K, Dobrashian R, Sambatakou H.  Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: Case series, proposed nomenclature and review. Clin Infect Dis 2003;37 (Suppl 3):S265-80.  
  6. Calcagno AM, Bignell E, Warn PA, Jones MD, Denning DW, Mühlschlegel F, Rogers TR, Haynes K. Candida glabrata Ste12 is required for virulence and nitrogen starvation induced filamentation. Mol Microbiol 2003;50:1309-1318. 
  7. Rodriguez-Tudela JL, Chryssanthou E, Petrikkou E, Mosquera J, Denning DW, Cuenca-Estrella M. Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Clin Microbiol 2003;41:5236-7. 
  8. Dodgson AR, Pujol C, Soll AJ, Denning DW, Fox AJ. Multilocus sequence typing (MLST) of Candida glabrata reveals geographically enriched clones. J Clin Microbiol 2003;41:5709-17. 

2004

  1. Birch M, Denning DW, Robson GD.  A comparison of extracellular phospholipase activities in clinical and environmental isolates of Aspergillus isolates.  Medical Mycology 2004;42:81-86.
  2. Hope WW, Denning DW. Invasive aspergillosis: the current and future challenges in diagnosis and therapy. Clin Microbiol Infect 2004;10:2-4.
  3. Pain A, Woodward J, Quail MA, Anderson MJ, Clark R, Collins M, Fosker N, Fraser A, Harris D, Larke N, Murphy L, Humphray S, O'Neil S, Pertea M, Price C, Rabbinowitsch E, Rajandream MA, Salzberg S, Saunders D, Seeger K, Sharp S, Warren T, Denning DW, Barrell B, Hall N. An insight into the genome of the most abundant opportunist human pathogen: analysis of 922 kb fragment of chromosome VIII of Aspergillus fumigatus. Fung Genet Biol 2004;41:443-53.
  4. Warn PA, Sharp A, Guinea J, Denning DW. Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J Antimicrob Chemother 2004;53:743-9.
  5. Hope WW, Padwell A, Guiver M, Denning DW. Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. J Infection 2004;49:136-40.
  6. Kamran M, Calcagno AM, Findon H, Bignell E, Jones MD, Warn PA, Hopkins P, Denning DW, Butler G, Rogers TR, Mühlschlegel F, Haynes K. Inactivation of the  ACE2 transcription factor gene in the fungal pathogen Candida glabrata results in hypervirulence. Eucaryotic Cell 2004;3:546-552.
  7. Calcagno AM, Bignell E, Rogers TR, Canedo M, Muhlschlegel FA, Haynes K. Candida glabrata Ste20 is involved in maintaining cell wall integrity and adaptation to hypertonic stress, and is required for wild-type levels of virulence. Yeast 2004;21:557-68.
  8. Nino-Vega GA, Sorais F, Calcagno AM, Ruiz-Herrera J, Martinez-Espinoza AD, San-Blas G. Cloning and expression analysis of the ornithine decarboxylase gene (PbrODC) of the pathogenic fungus Paracoccidioides brasiliensis. Yeast 2004;21:211-8.
  9. Hope WW, Denning DW. Optimising antifungal therapy for individual patients (Editorial). Intern Med J 2004;34:147-9.
  10. Hope WW, Denning DW. Antifungal therapy. MIMS Advances 2004 July: 8-11.
  11. Boyd AE, Modi S, Howard S, Moore CB, Keevil BG, Denning DW. Adverse reactions to high concentrations of voriconazole. Clin Infect Dis 2004;39:1241-4.
  12. Keevil B, Newman, Lockhart S, Moore CB, Howard S, Denning DW. Validation of an assay for voriconazole in serum samples using liquid chromatography- tandem mass spectrometry. Ther Drug Monit 2004;26:650-657.
2005
  1. O’Driscoll BR, Hopkinson LC, Denning DW. Mould sensitisation is common amongst patients with severe asthma requiring multiple hospital admissions in North West England. BMC Pulmonary Medicine 2005; 5:4.
  2. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005;43 (Suppl 1):S207-38.
  3. Paoletti M, Rydholm C, Schwier EU, Anderson MJ, Szakacs G, Lutzoni F, Debeaupuis JP, Latgé JP, Denning DW, Dyer PS Evidence for sexuality in the opportunistic fungal pathogen Aspergillus fumigatus. Curr Biol 2005;15:1242-8.
  4. Hope WW, Warn PA, Sharp A, Reed P, Keevil B, Louie A, Denning DW, Drusano G. Surface response modelling to examine the combination of amphotericin B and 5-fluorocytosine for treatment of invasive candidiasis. J Infect Dis 2005;192:673-80.
  5. Paisley D, Robson GD, Denning DW. Correlation between growth rate and in vivo virulence in Aspergillus fumigatus isolates. Med Mycol 2005;43:397-402.
  6. Nierman WC, May G, Kim HS, Anderson MJ, Chen D, Denning DW. What the Aspergillus genomes have told us. Med Mycol 2005;43 Suppl 1:S3-5.
  7. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infectious Diseases 2005:9:609-22.
  8. Pasqualotto AC, Denning DW. Diagnosis of invasive fungal infections – current limitations of classical methods and new diagnostic methods. Europ Oncol Rev 2005; REV:1-11.
  9. Warn PA, Sharp A, Morrissey G, Denning DW. Activity of aminocandin (IP960) compared to amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole resistant strains of Candida tropicalis. J Antimicrob Chemother 2005; 56:590-3.
  10. Nierman W, Pain A, Anderson MJ, Wortman J, Kim HS, Arroya J, Berriman B, Abe K, Archer DB, Bermejo C, Bennett J, Bowyer P, Chen D, Collins M, Coulsen R, Davies R, Dyer PS, Farman M, Federova N, Federova N, Feldblyum TV, Fisher R, Fosker N, Fraser A, García JL, García MJ, Goble A, Goldman GH, Gomi K, Griffith-Jones S, Gwilliam R, Haas B, Harris D, Horiuchi H, Huang J, Humphrey S, Jiménez J, Keller N, Khouri H, Kitamoto K, Kobayashi T, Konzack S, Kulkarni R, Kumagai T, Lafton A, Latgé JP, Lord A, Lu C, Majoros WH, May GS, Miller BL, Mohamoud Y, Molina M, Monod M, Mouyna I, Mulligan S, Murphy L, O'Neil S, Paulsen I, Penalva MA, Pertea M, Price C, Pritchard BL, Quail MA, Rabbinowitsch E, Rawlins N, Rajandream M-A, Reichard U, Renauld H, Robson GD, de Córdoba SR, Rodríguez-Peña JM, Ronning CM, Rutter S, Salzberg SL, Sanchez S, Sánchez-Ferrero JC, Saunders D, Seeger K, Squares R, Squares S, Takeuchi T, Tekaia F, Turner G, Vazquez de Aldana CR, Weidman J, White O, Woodward J, Yu J-H, Fraser C, Galagan JE, Asai K, Machida M, Hall N, Barrell B, Denning DW. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 2005;438:1151-6.
  11. Woodcock AA, Steel N, Moore CB, Howard SJ, Custovic A, Denning DW. Fungal contamination of bedding.(2006) Allergy. Jan; 61 (1): 140-2.
  12. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. (2006) J Antimicrob Chemother. Jan; 57(1):135-8. Epub 2005 Nov 10.
  13. Strahilevitz J, Rahav G, Schroers H, Summerbell RC, Amitai Z. Goldschmied-Reouven A, Rubinstein E, Schwammenthal Y, Feinberg MS, Siegman-Igra Y, Bash E, Polacheck I, Zelazny A, Howard SJ, Cibotaro P, Shovman O, Keller N. An outbreak of invasive Phialemonium infection linked to intra-cavernous penile injections for the treatment of impotence. (2005). Clinical Infectious Disease 40: 781- 786.
  14. Jung WH, Warn P, Ragni E, Popolo L, Nunn CD, Turner MP, Stateva L. Deletion of PDE2, the gene encoding the high-affinity camp phosphodiesterase results in changes of the cell wall and membrane in Candida albicans. (2005) Yeast 22 (4):285-94.
2006
  1. Woodcock AA, Steele N, Moore CB, Howard SH, Custovic A, Denning DW, Fungal contamination of bedding.  Allergy 2006; 61:140-2.
  2. Hamer EC, Moore CB, Denning DW.  Comparison of two fluorescent whiteners, Calcofluor  and Blankophor, in the detection of fungal elements in clinical specimens in the diagnostic laboratory.  Clin Microbiol Infect 2006;12:181-4.
  3. Warn PA, Sharp A, Denning DW.  In Vitro Activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug) against Aspergillus spp.J Antimicrob Chemother 2006;57:135-8.
  4. Sambatakou H, Dupont B. Lode H, Denning DW.  Efficacy and safety of voriconazole in the treatment of sub-acute invasive and chronic pulmonary aspergillosis.  Am J Med 2006;119:527.e17-24.
  5. Sambatakou H. Pravica V, Hutchinson I, Denning DW.  Cytokine profiling of pulmonary aspergillosis.  Int J Immunogenetics 2006;33:297-302.
  6. Pasqualotto AC, Denning DW.  Post-operative aspergillosis.  Clin Microbiol Infect 2006;12:1060-76.
  7. Howard SJ, Walker SL, Andrew SM, Borman AM, Johnson EM, Denning DW.  Sub-cutaneous phaeohyphomycosis caused by Cladophialophora devresii in a United Kingdom resident.  Med Mycol 2006;44:553-6.
  8. Lass-Florl C, Cuenca-Estrella M, Denning DW, Rodiguez-Tudela, JL.  Antifungal susceptibility testing in Aspergillus spp. According to EUCAST methodology.  Med Mycol 2006;44(Suppl 1):319-25.
  9. Bowyer P, Blightman O, Denning DW.  Relative reactivity and comparative genomic analysis of Aspergillus allergens used in serological tests.  Med Mycol 2006;44 (Suppl 1):24-28.
  10. Wortman JR, Fedorova N, Crabtree J, Joardar V, Maiti R, Haas BJ, Amedeo P, Lee E, Angiuoli SV, Jiang B, Anderson MJ, Denning DW, White OR, Nierman WC.  Whole genome comparison of the A.fumigatus family.  Med Mycol 2006;44(Suppl 1):3-7.
  11. Bowyer P, Fraczek M, Denning DW.  A comparative genomic analysis of fungal allergens reveals the presence of multiple cross reactive proteins.  BMC Genomics 2006;7:251.
  12. Hope WW, Warn PA, Sharp A, Howard S, Kasai M, Louie A, Walsh TJ, Drusano G, Denning DW.  Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect.  Antimicrob Ag Chemother.  2006;50:3680-8.
  13. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW.  Multi-azole resistance in Aspergillus fumigatus.  Int J Antimicrob Ag 2006;28:450-3.
  14. Warn PA, Sharp A, Mosquera J, Spickermann J, Schmidtt-Hoffmann A, Heep M, Denning DW. Comparative in vivo activity of BAL4815, the active component of the Prodrug BAL8557 in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 2006;58:1198-207.
2007
  1. Hope WW, Drusano G, Moore CB, Sharp A, Louie A, Walsh TJ, Denning DW, Warn PA. Effect of neutropenia and treatment delay on the response to antifungal drugs in experimental invasive candidiasis. Antimicrob Ag Chemother 2007;51:285-95.
  2. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, Chryssantou E, Warn P, Denning DW, Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M. Statistical analyses of correlation for fluconazole minimal inhibitory concentrations and Candida spp. for standard methodologies of EUCAST (E.Dis. 7.1) and CLSI (M27 A2). J Clin Microbiol 2007; 45:109-11.
  3. Pasqualotto AC, Denning DW, Anderson MJ. A cautionary tale: the lack of consistency in allele sizes between two laboratories for a published Multi-Locus Microsatellite Typing (MLMT) system. J Clin Microbiol 2007;45:522-8.
  4. Pasqualotto AC, Denning DW. Generic substitution of itraconazole resulting in clinical failure and resistance. Int J Antimicrob Ag 2007;30:93-4.
  5. Vaid M, Savneet Kaur S, Sambatakou H, Madan T, Denning DW, Sarma PU. Association of distinct alleles of MBL and SP-A with chronic cavitary pulmonary aspergillosis. Clinical Chemistry and Laboratory Medicine 2007;45:183-6.
  6. Hedayati M, Pasquallotto A, Warn PA, Bowyer P, Denning DW. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007;153:1677-92.
  7. Hope WW, Shoham S, Walsh TJ.The pharmacology and clinical use of caspofungin. Expert Opin Drug Metab Toxicol 2007 3:263-74.
  8. Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, Kelaher AM, Hughes JE, Cotton MP, Cotten CJ, Bacher J, Tripathi S, Bermudez L, Maugel TK, Zerfas PM, Wingard JR, Drusano GL, Walsh TJ. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 2007;195:455-66.
  9. Pasqualotto AC, Howard S, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15-years experience from the United Kingdom. J Antimicrob Chemother 2007:59:791-3.
  10. Hope WW, Warn PA, Sharp A, Reed P, Keevil B, Louie A, Walsh TJ, Denning DW, Drusano G. Optimization of the dosage of 5-fluorocytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. Antimicrob Ag Chemother 2007; 51:3760-2.
  11. Rosa D, Pasquallotto A, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. Med Mycol 2007;45: Aug 28:1-7.
  12. Schröeder R, Michelon T, Wurdig J, Fagundes I, Schio S, Sanchez L, Camargo JJ, Sukkienik TC, Pasqualotto AC, Neumann J. The incidence of cytomegalovirus infection in lung transplant recipients under universal prophylaxis with intravenous ganciclovir. Braz J Infect Dis 2007;11:212-4.
  13. Pasqualotto AC, de Moraes AB, Zanini RR, Severo LC. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol 2007;28:799-804.
  14. Aquino VR, Goldani LZ, Pasqualotto AC. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia 2007;163:191-202.
  15. Rosa DD, Pasqualotto AC, Schwartsmann G. The egos and the goals of reporting results. Oral Dis 2007; 13:251.
  16. Pasqualotto AC, Denning DW. An aspergilloma caused by Aspergillus flavus. Med Mycol 2007;45:1-4.
  17. Rokas A, Payne G, Federova ND, Baker SE, Machida M, Yu J, Georgianna DR, Dean RA, Bhatnagar D, Cleveland TE, Wortman JR, Maiti R, Joardar V, Amedeo P, Denning DW, Nierman WC. What can comparative genomics tell us about species concepts in the genus Aspergillus? Mycol Res 2007;59:11-17.
2008
  1. Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. Med Mycol 2008;46:85-91.
  2. Arendrup MC, Perkhofer S, Howard SJ, Perlin D, Latgè JP, Lass-Flörl C. In vivo confirmation of in vitro loss of susceptibility against caspofungin and azoles in clinical Aspergillus fumigatus isolates. Antimicrob Ag Chemother 2008;52:3504-11.
  3. Pasqualotto AC, Denning DW. An aspergilloma caused by Aspergillus flavus. Med Mycol 2008;46:275-8.
  4. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infection. J Antimicrob Chemother 2008; 61(Suppl 1); i19-i30.
  5. Carvalho A, Pasqualotto AC, Romani L, Denning DW, Rodrigues F. Polymorphisms in Toll-like receptors(TLR) genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008;197:618-621.
  6. Pasqualotto AC, Shah M, Wynn R, Denning DW. Voriconazole plasma monitoring. Arch Dis Child 2008;93:578-81.
  7. The European Committee on Antimicrobial Susceptibility Testing – Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Fegeler W, Gaustad P, Lass-Flörl C, Moore CB, Richardson M, Schmalreck A, Velegraki A, Verweij P). EUCAST Technical Note on fluconazole. Clin Microbiol Infect 2008;14:193-195.
  8. Rashid R, Pasquallotto AC, Denning DW. A case of spotted fever group rickettsiosis imported into the United Kingdom and treated with ciprofloxacin: a case report. J Med Case Reports 2008;2:98.
  9. Federova N, Khaldi N, Joardar V, Maiti R, Amedeo, Anderson MJ, Crabtree J, Badger J, Albarraq A, Angiuoli S, Bussey H, Bowyer P, Cotty PJ, Dyer P, Egan A, Galens K, Fraser C, Haas B, Inman J, Kent, Lemieux S, Malavazi I, Orvis  J, Roemer T, Ronning C, Silva J, Sundaram J, Sutton G, Turner G, Venter JC, White OR, Whitty B, Youngman P, Wolfe K, Goldman GH, Wortman JR, Jiang B, Denning DW, Nierman WC. Genomic islands in the pathogenic filamentous fungus Aspergillus fumigatus. PLoS Genet 2008;4:e1000046.
  10. Rodriguez-Tudela JL, Arendrup M, Chryssanthou E, Dannaoui E, Denning DW, Donnelly JP, Schmalrek A, Verweij PE, Cuenca-Estrella M. Minimal inhibitory concentration distributions and epidemiological cut-offs of amphotericin B, flucytosine, fluconazole, itraconazole and voriconazole for Candida spp. using the EUCAST methodology for susceptibility testing. Clin Microbiol Infect 2008;14:982-4.
  11. Rodriguez-Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Fegeler W, Gaustad P, Klimko N, Lass-Florl C, Moore CB, Richardson M, Schmalreck A, Stenderup J, Velegraki A, Verweij P, and Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.  EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008; 14: 982-984.
  12. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Op Infect Dis 2008; 21: 580-86.
  13. Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, Pura M,  MD, Bøe Wolff A, Husebye H, Lilic D, Ryan KR, Gennery AR, Cant AJ, Abinun M, Spickett GP, Arkwright PD, Denning DW, Costigan C, Dominguez M, McConnell V, Willcox N, Meager A. Autoantibodies against type I Interferons: alternative diagnostic criteria for Auto-immune polyendocrinopathy candidiasis ectodermal dystrophy (APECED). J Clin Endocrinol Metab 2008;93:4389-97.
  14. Ryan KR, Hong M, Arkwright PD, Gennery AR, Costigan C, Dominguez M, Denning DW, McConnell V, Cant AJ, Abinun M, Spickett GP, Lilic D. Impaired Dendtritic Cell Maturation and Cytokine Production in Patients with Chronic Mucocutanous Candidiasis with or without APECED. Clin Exp Immunol 2008;154:406-14.
  15. Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol 2008 Jul 25:1-10.

back to top of page

<HOME PAGE <PREVIOUS PAGE